Antiproliferative effect in rat vascular smooth muscle cells by osthole, isolated from Angelica pubescens.
The antiproliferative effect of osthole on rat vascular smooth muscle cells was examined in this study. A number of mitogenic agents, e.g., foetal-calf serum (10%, v/v) and platelet-derived growth factor (20 ng/ml), and pharmacological agents, e.g., serotonin (10 microM), ionomycin (3 nM), phorbol 12,13-dibutyrate (20 nM) and phorbol myristate acetate (200 nM), were used to induce DNA synthesis in rat vascular smooth muscle cells; these effects were concentration dependently inhibited by osthole and the half-maximal inhibition (IC50) occurred at 13.6 +/- 1.8, 11.8 +/- 1.3, 7.9 +/- 0.9, 7.1 +/- 0.2, 7.8 +/- 0.2 and 8.6 +/- 0.4 microM, respectively. Osthole itself increased the cyclic AMP and cyclic GMP formations in a concentration-dependent manner; it synergistically increase cyclic AMP and cyclic GMP levels induced by forskolin and sodium nitroprusside, respectively. After 48 h deprivation of serum, cells were re-stimulated with serum and the cell cycle was observed by flow cytometry; treatment of cells with osthole (100 microM) caused a block of serum-inducible cell cycle progression at a point before the G1-S boundary. The addition of osthole (100 microM) at various times after serum addition to serum-deprived cells showed full inhibition of DNA synthesis even when added 6 h after serum. The cell cycle progression block was gradually lost as the delay from serum to osthole application was increased from 6 to 18 h. The effect of osthole on serum-stimulated [3H]thymidine incorporation into endothelial cells was examined and the IC50 value (158.7 +/- 2.7 microM, n = 6) was obtained; it exhibited greater potency (12-fold) for vascular smooth muscle cells as compared with endothelial cells as an antiproliferative agent. These results suggest that osthole is a selective antiproliferative agent in vascular smooth muscle cells. The antiproliferative effect occurs at the early G1 phase of the cell cycle and is due to the increase in cyclic AMP and cyclic GMP contents.
Guh
J H
JH
Pharmacological Institute, College of Medicine, National Taiwan University, Taipei.
Yu
S M
SM
Ko
F N
FN
Wu
T S
TS
Teng
C M
CM
D000818:Animals; D001011:Aorta / Q000187:drug effects*; D002121:Calcium Channel Blockers / Q000494:pharmacology*; D002452:Cell Count / Q000187:drug effects; D005576:Colforsin / Q000494:pharmacology; D003374:Coumarins / Q000494:pharmacology*; D004305:Dose-Response Relationship, Drug; D009131:Muscle, Smooth, Vascular / Q000187:drug effects*; D051381:Rats; D013936:Thymidine / Q000494:pharmacology; D013997:Time Factors
D002121:Calcium Channel Blockers; D003374:Coumarins; D005576:Colforsin; D013936:Thymidine; C046627:osthol